Ozlem Kurnaz-Gomleksiz1, Bahar Canbay Torun2, Turgay Isbir3, Turker Bulut4, Necmettin Sokucu4, Hulya Yilmaz-Aydogan5, Emel Canbay6. 1. Altınbaş University, Faculty of Medicine, Department of Medical Biology, Istanbul, Turkey. 2. Istinye University, Faculty of Medicine, Department of General Surgery, Istanbul, Turkey. 3. Yeditepe University, Department of Molecular Department of Medical Biology, Faculty of Medicine, Yeditepe University, Istanbul, Turkey. 4. Istanbul University, Istanbul Medical Faculty, Department of General Surgery, Istanbul, Turkey. 5. Istanbul University, Aziz Sancar Institute of Experimental Medicine, Department of Molecular Medicine, Istanbul, Turkey. 6. NPO Treatment Center for Peritoneal Disseminated Diseases (NPO HIPEC ISTANBUL), Istanbul, Turkey drecanbay@gmail.com.
Abstract
BACKGROUND/AIM: This study aimed to determine the role of the peroxisome proliferator-activated receptor-gamma (PPARg) C161T genotype and allele frequencies in predisposition to colorectal cancer (CRC). PATIENTS AND METHODS: PPARg C161T (His447His; rs3856806) gene polymorphisms were determined by polymerase chain reaction-restriction fragment length polymorphism analysis in patients with CRC (n=101) and controls (n=238). RESULTS: The T161 allele (CT+TT genotypes) of PPARg C161T polymorphism was associated with CRC development (p<0.001; OR=3.239, 95%CI=1.997-5.252). Subgroup analysis showed that the T161 allele was associated with a 3.056-fold increased risk for colon cancer (CC) (p<0.001; 95%CI=1.709-5.464) and 3.529-fold increased risk for rectal cancer (RC) (p<0.001; 95%C=1.784-6.981). Frequencies of the T161 allele were also higher in total CRC and CC patients with poorly differentiated tumors (p<0.001, c2=30,601, OR=3.109; 95%CI=1.970-4.906 and p<0.001, Fisher exact test, respectively). CONCLUSION: PPARg T161 allele carriers have increased risk for developing CRC.
BACKGROUND/AIM: This study aimed to determine the role of the peroxisome proliferator-activated receptor-gamma (PPARg) C161T genotype and allele frequencies in predisposition to colorectal cancer (CRC). PATIENTS AND METHODS: PPARg C161T (His447His; rs3856806) gene polymorphisms were determined by polymerase chain reaction-restriction fragment length polymorphism analysis in patients with CRC (n=101) and controls (n=238). RESULTS: The T161 allele (CT+TT genotypes) of PPARg C161T polymorphism was associated with CRC development (p<0.001; OR=3.239, 95%CI=1.997-5.252). Subgroup analysis showed that the T161 allele was associated with a 3.056-fold increased risk for colon cancer (CC) (p<0.001; 95%CI=1.709-5.464) and 3.529-fold increased risk for rectal cancer (RC) (p<0.001; 95%C=1.784-6.981). Frequencies of the T161 allele were also higher in total CRC and CC patients with poorly differentiated tumors (p<0.001, c2=30,601, OR=3.109; 95%CI=1.970-4.906 and p<0.001, Fisher exact test, respectively). CONCLUSION: PPARg T161 allele carriers have increased risk for developing CRC.
Authors: A Meirhaeghe; L Fajas; N Helbecque; D Cottel; P Lebel; J Dallongeville; S Deeb; J Auwerx; P Amouyel Journal: Hum Mol Genet Date: 1998-03 Impact factor: 6.150
Authors: Maureen A Murtaugh; Khe-Ni Ma; Bette J Caan; Carol Sweeney; Roger Wolff; Wade S Samowitz; John D Potter; Martha L Slattery Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-05 Impact factor: 4.254
Authors: Christine L E Siezen; Astrid I M van Leeuwen; Nicolien R Kram; Manon E M Luken; Henk J van Kranen; Ellen Kampman Journal: Carcinogenesis Date: 2004-11-18 Impact factor: 4.944
Authors: Martha L Slattery; Karen Curtin; Roger Wolff; Khe Ni Ma; Carol Sweeney; Maureen Murtaugh; John D Potter; Theodore R Levin; Wade Samowitz Journal: Cancer Causes Control Date: 2006-04 Impact factor: 2.506